Compare Roblox Corp (RBLX) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roblox Corp vs Zimmer Biomet Holdings Inc — how do they compare? Roblox Corp trades at $48.09 (market cap $32.52B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Roblox Corp is the larger of the two by market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Roblox Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Roblox Corp for 93 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| RBLX | ZBH | |
|---|---|---|
Market Cap | $32.52B | $16.95B |
Volume | 14,552,045 | 2,505,240 |
Sector | Technology | Health |
52-Week High | $138.56 | $103.98 |
52-Week Low | $35.54 | $79.58 |
Typical Hold Time | 93 Days | 89 Days |
Enterprise Value | $31.34B | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Roblox (RBLX) trades at $45.53, down 1.9% on the day, with technical indicators showing bearish momentum despite recent earnings beats. The company continues to demonstrate strong revenue growth, reaching $4.89 billion in 2025, but remains unprofitable with a net income margin of -17.61%. Recent analyst downgrades from Jefferies highlight concerns about bookings growth, creating mixed sentiment around the stock's near-term prospects.
While Roblox shows impressive revenue expansion and strong cash flow generation, persistent losses and high valuation metrics present significant risks. The stock faces headwinds from technical weakness and analyst skepticism, though long-term growth potential in the gaming platform remains intact. Investors must weigh the company's growth trajectory against ongoing profitability challenges.
Zimmer Biomet (ZBH) trades at $88.91, up 0.47% today, with a bearish technical signal from moving averages. The company reported Q2 2026 EPS of $2.07, beating estimates, and raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23B, though net income margin declined to 8.56%. The stock is supported by a quarterly dividend of $0.24 and a consensus price target of $103.11, suggesting potential upside.
The outlook is mixed: strong fundamentals and analyst optimism contrast with technical weakness. Investment opportunities include consistent earnings beats and dividend income, but risks involve rising debt levels and competitive pressures in the medical technology sector. The stock's current valuation at a P/E of 21.57 appears reasonable if growth continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Roblox Corp
Roblox operates an online video game platform that lets young gamers create, develop, and monetize games (or experiences) for other players. The firm effectively offers its developers a hybrid of a game engine, publishing platform, online hosting and services, marketplace with payment processing, and social network. The platform is a closed garden that Roblox controls, earning revenue in multiple places while benefiting from outsourced game development. Unlike traditional video game publishers, Roblox is more focused on the creation of new tools and monetization techniques for its developers then creating new games or franchises. Roblox is increasingly focused on creating a metaverse that moves beyond games toward experiences like concerts, education, and even business management.
Read more on RBLX →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
